Curemark, LLC announced the appointment of Afia Asamoah to its Board of Directors, effective immediately. She is currently Head of Legal for the health business unit of Google. Along with leading a global team of lawyers, Afia is a member of the senior management team, guiding strategy and managing risk for Google Health.
As a leader in strategy development, Ms. Asamoah has helped to shape Google’s entry into the healthcare space, including the formation of a standalone Alphabet company, Verily Life Sciences.
Prior to working at Google, she served as Special Assistant in the Office of the Commissioner at the U.S. Food and Drug Administration (FDA), where she received numerous awards including the FDA Commissioner’s Special Citation. Afia is recognized as a leader and digital health innovator — in 2020, she was named “one of the 10 most influential minority healthcare executives” by FierceHealthcare.
“I could not be more thrilled to have Afia as a part of the Curemark team,” states Dr. Joan Fallon, Curemark’s CEO. “Her experience, vision for reimagining healthcare, equitable distribution of treatment and improving healthcare outcomes is completely aligned with our mission here at Curemark.”
Ms. Asamoah states, “I am honored to join Curemark’s board as an independent Director. I have known Dr. Fallon for years, and am inspired by her team’s patient-centered approach to developing therapies for autism and other neurological diseases. I look forward to applying my experience, energy, and passion to support Curemark’s leadership team in their work for children and families.”
ABOUT CUREMARK
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of autism, schizophrenia and Parkinson’s disease, ADHD and addiction. For additional information, please visit our website at http://www.curemark.com or follow @Curemark on Twitter.
